FHTX Foghorn Therapeutics Inc.

13.61
-0.6  -4%
Previous Close 14.21
Open 13.74
52 Week Low 8.01
52 Week High 28.265
Market Cap $504,816,513
Shares 37,091,588
Float 19,645,857
Enterprise Value $486,154,465
Volume 96,814
Av. Daily Volume 60,895
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
FHD-286
Acute myeloid leukemia (AML)
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
FHD-286
Uveal melanoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
FHD-609
Synovial sarcoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.

    2021 Jefferies London Healthcare Conference
    Format: Virtual presentation and investor 1x1 meetings
    The presentation will be available on-demand starting Thursday, November 18, 2021, at 8:00am GMT / 3:00am ET through Friday, November 19, 2021, at 5:00pm GMT / 12:00pm ET.

    Please find a link to the presentation here.

    A webcast can also be accessed under "Events & Presentations…

    CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.

    2021 Jefferies London Healthcare Conference

    Format: Virtual presentation and investor 1x1 meetings

    The presentation will be available on-demand starting Thursday, November 18, 2021, at 8:00am GMT / 3:00am ET through Friday, November 19, 2021, at 5:00pm GMT / 12:00pm ET.

    Please find a link to the presentation here.

    A webcast can also be accessed under "Events & Presentations" in the Investors section of the Company's website, www.foghorntx.com

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics Inc.

    Gregory Kelley, Ogilvy

    Investor Relations Contact:

    Ben Strain, Foghorn Therapeutics Inc.

    Hans Vitzthum, LifeSci Advisors

    617-430-7578



    Primary Logo

    View Full Article Hide Full Article
  2. -- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma

    -- Continue to enroll patients in phase 1 clinical trials of FHD-286, an inhibitor of BRG1/BRM, in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML)

    -- Presented an overview of Company's proprietary protein degrader platform and clinical stage asset, FHD-609, at the 4th Annual Targeted Protein Degradation Summit

    -- Continued advancement of broad therapeutic pipeline that includes protein degraders, enzymatic inhibitors and transcription factor disruptors targeting cancers impacted by breakdowns in the chromatin regulatory

    -- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma

    -- Continue to enroll patients in phase 1 clinical trials of FHD-286, an inhibitor of BRG1/BRM, in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML)

    -- Presented an overview of Company's proprietary protein degrader platform and clinical stage asset, FHD-609, at the 4th Annual Targeted Protein Degradation Summit

    -- Continued advancement of broad therapeutic pipeline that includes protein degraders, enzymatic inhibitors and transcription factor disruptors targeting cancers impacted by breakdowns in the chromatin regulatory system

    CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update in conjunction with the Company's 10-Q filing for the quarter ended September 30, 2021. With an initial focus in oncology, Foghorn's Gene Traffic Control Platform® and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

    "During the third quarter of 2021, we continued to advance our robust pipeline targeting the chromatin regulatory system," said Adrian Gottschalk, President and Chief Executive Officer. "In August, we dosed the first patient in the phase 1 study of FHD-609, our potent, selective, intravenous, small molecule protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma. We continue to enroll patients in the phase 1 studies of FHD-286, an inhibitor of BRG1/BRM being studied in metastatic uveal melanoma and relapsed or refractory AML and MDS, areas of high unmet medical need. These studies are progressing through dose escalation, and we are pleased with the execution of the enrollment to date and look forward to sharing initial data from these studies in the future."

    Continued Mr. Gottschalk, "Beyond these two clinical programs, we continue to expand our deep pipeline of precision therapeutic candidates targeting different aspects of the chromatin regulatory system in cancer, including enzymatic inhibitors, transcription factor disruptors and over eight protein degrader programs such as our BRM-selective degrader, ARID1B degrader and other undisclosed programs."

    Recent Corporate Highlights:

    • Dosed First Patient with FHD-609. In August, Foghorn announced the dosing of the first patient in its first-in-human clinical trial of FHD-609. FHD-609 is a highly potent, selective, intravenous, protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma with the intention to expand into additional indications, including SMARCB1 deleted tumors. Sites for the phase 1 study have been activated and are currently dosing patients. To learn more about this study, please visit ClinicalTrials.gov.
    • Participation at the 4th Annual Targeted Protein Degradation Conference. In October 2021, Foghorn presented at the 4th Annual Targeted Protein Degradation Conference providing an overview of the Company's degrader capabilities and its phase 1 asset FHD-609, including the programs compelling in-vitro and in-vivo profile supporting first-in-human studies. Within Foghorn's degrader platform, the Company is actively advancing more than eight targeted protein degrader programs including its BRM-selective degrader for BRG1 mutated cancers and its selective ARID1B program for ARID1A mutated cancers which impacts more than 175,000 patients a year. Additional information on the Summit can be found here.

    Key Upcoming Milestones:

    • FHD-286 data. Foghorn expects to have initial data from the Company's phase 1 studies of FHD-286 in both metastatic uveal melanoma and relapsed/refractory AML and MDS as early as the fourth quarter of 2021.
    • FHD-609 data. Foghorn expects to have initial data from the Company's phase 1 study in synovial sarcoma as early as the first half of 2022.

    Upcoming Events

    • 4th Annual Evercore ISI HealthCONx Conference, November 30th-December 2nd, 2021

    Financial Condition

    Foghorn reported cash, cash equivalents and marketable securities of $120.8 million as of September 30, 2021, as compared to $141.3 million as of June 30, 2021, and $185.8 million as of December 31, 2020.

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Forward-Looking Statements

    This press release contains "forward-looking statements" regarding the Company's clinical programs for FHD-286 and FHD-609 and the Company's research pipeline. Forward-looking statements include statements regarding the Company's clinical trial, product candidates and research efforts and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of filing an IND for our product candidates and other factors set forth under the heading "Risk Factors" in the Company's Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics Inc.

    Gregory Kelley, Ogilvy

    Investor Relations Contact:

    Ben Strain, Foghorn Therapeutics Inc.

    Hans Vitzthum, LifeSci Advisors

    617-430-7578



    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that David Millan, PhD, Foghorn's Vice President of Chemistry, will be presenting at the 4th Annual Targeted Protein Degradation Summit, which is being held virtually October 26-29, 2021. With an initial focus in oncology, Foghorn's Gene Traffic Control Platform® and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

    "At Foghorn, we have spent the last four years building a drug discovery platform including…

    CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that David Millan, PhD, Foghorn's Vice President of Chemistry, will be presenting at the 4th Annual Targeted Protein Degradation Summit, which is being held virtually October 26-29, 2021. With an initial focus in oncology, Foghorn's Gene Traffic Control Platform® and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

    "At Foghorn, we have spent the last four years building a drug discovery platform including robust protein degrader capabilities that we have applied to drugging the chromatin regulatory system at scale, in context, and in an integrated fashion," stated Dr. Millan. "We use this part of our platform to evaluate and optimize novel heterobifunctional degrader compounds derived from our library of drug-like linkers in combination with E3 ligase binders.  We have developed a robust suite of physiologically relevant screening assays that measure protein kinetics and enable us to generate and model ternary complexes."

    "Foghorn is actively advancing over eight protein degrader programs through both pre-clinical and clinical activities. Among these is FHD-609, a potent and highly selective heterobifunctional degrader of BRD9 with encouraging therapeutic potential as a new treatment for synovial sarcoma, an aggressive soft tissue cancer with limited treatment options. Having recently entered the clinic, FHD-609 is representative of the innovative capabilities of our targeted protein degradation platform that positions us to be a leader in the development of protein degrader therapeutics. We continue to advance our understanding of this emerging biology through multiple ongoing degrader programs, and I am excited to share our learnings and progress at this year's TPD Summit," concluded Dr. Millan.

    Presentation details:

    Title:         Discovery of FHD-609: A Potent & Selective Intravenous Heterobifunctional Degrader of BRD9

    Day:         Wednesday, October 27

    Time:        4:45pm ET / 1:45pm PT

    Additional information on the Summit can be found here.

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Forward-Looking Statements

    This press release contains "forward-looking statements" regarding the Company's clinical programs for FHD-609 and its research pipeline. Forward-looking statements include statements regarding the Company's clinical trial, product candidates and research efforts and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of filing an IND for our product candidates and other factors set forth under the heading "Risk Factors" in the Company's Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics Inc.

    Gregory Kelley, Ogilvy

    Investor Relations Contact:

    Ben Strain, Foghorn Therapeutics Inc.

    Hans Vitzthum, LifeSci Advisors

    617-430-7578

     



    Primary Logo

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

    Events:

    Morgan Stanley Virtual Annual Global Healthcare Conference
    Format: Fireside Chat and investor 1x1 meetings
    Thursday, September 9, 2021
    11:45am ET
    Please find a link to the presentation here. A replay will be available for 90 days.

    H.C. Wainwright 23rd Annual Global Investment Conference
    Format: Presentation and investor 1x1 meetings
    Monday, September 13, 2021
    All company…

    CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

    Events:

    Morgan Stanley Virtual Annual Global Healthcare Conference

    Format: Fireside Chat and investor 1x1 meetings

    Thursday, September 9, 2021

    11:45am ET

    Please find a link to the presentation here. A replay will be available for 90 days.

    H.C. Wainwright 23rd Annual Global Investment Conference

    Format: Presentation and investor 1x1 meetings

    Monday, September 13, 2021

    All company presentations will be available on-demand beginning at 7:00am ET

    Please find a link to the presentation here.

    A webcast of both presentations can also be accessed under "Events & Presentations" in the Investors section of the Company's website, www.foghorntx.com

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics Inc.

     

    Gregory Kelley, Ogilvy

     

    Investor Relations Contact:

    Ben Strain, Foghorn Therapeutics Inc.

     

    Hans Vitzthum, LifeSci Advisors

    617-430-7578

     



    Primary Logo

    View Full Article Hide Full Article
  5. FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

    Foghorn's first protein degrader program to enter the clinic; continues pre-clinical work on other protein degrader programs for broad range of cancers

    Significant unmet need in synovial sarcoma with limited therapeutic options

    CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that the first patient has been dosed in a first-in-human clinical trial of FHD-609, which is being developed as a treatment for synovial sarcoma. With an…

    FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

    Foghorn's first protein degrader program to enter the clinic; continues pre-clinical work on other protein degrader programs for broad range of cancers

    Significant unmet need in synovial sarcoma with limited therapeutic options

    CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that the first patient has been dosed in a first-in-human clinical trial of FHD-609, which is being developed as a treatment for synovial sarcoma. With an initial focus in oncology, Foghorn's Gene Traffic Control Platform® and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

    "FHD-609 is our first protein degrader to enter the clinic, marking an exciting milestone for this program and further validating the potential of our Gene Traffic Control platform and our capabilities of creating precision medicines based on targeted protein degradation," said Adrian Gottschalk, President and Chief Executive Officer. "Foghorn has a broad pipeline of protein degrader programs, and we continue to advance these precision medicines towards clinical development."

    FHD-609 is a potent, selective protein degrader of BRD9 (bromodomain-containing protein 9), a subunit of ncBAF (non-canonical BAF complex). Substantially all synovial sarcoma cancers contain a translocation, a type of mutation between a BAF subunit gene SS18 and another set of genes SSX. These mutations render the cancer genetically dependent upon BRD9, what is commonly referred to as a synthetic lethal relationship.

    FHD-609 is the second program to enter the clinic from Foghorn's diverse pipeline targeting genetically determined dependencies within the chromatin regulatory system.   In May 2021, the company announced the first patient dosed in first-in-human clinical trials of FHD-286, a selective inhibitor of the BAF chromatin remodeling complex ATPases BRG1 and BRM, in metastatic uveal melanoma (mUM) relapsed/refractory acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS).   To learn more about these studies in FHD-286, please visit ClinicalTrials.gov. (Link here for mUM and here for AML and MDS)

    Sam Agresta M.D., M.P.H., Chief Medical Officer, said, "Synovial sarcoma is a rare, often aggressive malignancy with limited therapeutic options. In preclinical studies, FHD-609 has been shown to selectively degrade BRD9, taking advantage of a synthetic lethal relationship with the SS18-SSX translocation. We look forward to initial clinical data in the first half of 2022."

    The FHD-609 clinical trial in advanced synovial sarcoma is first-in-human and first-in-class. The open-label, monotherapy, dose-escalation and dose-expansion study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of FHD-609 administered intravenously. To learn more about the first-in-human clinical trial of FHD-609 in synovial sarcoma, please visit ClinicalTrials.gov.

    About FHD-609

    FHD-609 is a potent, selective, intravenously administered protein degrader of BRD9, a component of the ncBAF complex. Preclinical studies have demonstrated tumor growth inhibition in synovial sarcoma, a cancer genetically dependent on BRD9.

    About Synovial Sarcoma

    Synovial sarcoma is a rare, often aggressive soft tissue sarcoma that originates from different types of soft tissue, including muscle or ligaments. Synovial sarcoma can occur at any age but is most common among adolescents and young adults. It represents around 5-10% of all soft tissue sarcomas, with ~800 new cases each year in the United States. Surgery remains the most effective treatment for synovial sarcoma, and there are limited therapeutic treatment options.

    About FHD-286

    FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.

    About AML

    Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic mutations. It is diagnosed in about 20,000 people every year in the United States.

    About Uveal Melanoma

    Uveal (intraocular) melanoma is a rare eye cancer that forms from cells that make melanin in the iris, ciliary body, and choroid. It is the most common eye cancer in adults. It is diagnosed in about 2,000 adults every year in the United States and occurs most often in lightly pigmented individuals with a median age of 55 years. However, it can occur in all races and at any age. UM metastasizes in approximately 50% of cases, leading to very poor prognosis.

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Forward-Looking Statements

    This press release contains "forward-looking statements" regarding the Company's clinical programs for FHD-609 and FHD-286, including the results therefrom and the timing of clinical data relating thereto, and its research pipeline. Forward-looking statements include statements regarding the Company's clinical trials, product candidates and research efforts and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of regulatory filings relating to our product candidates and other factors set forth under the heading "Risk Factors" in the Company's Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics Inc.

    Gregory Kelley, Ogilvy

    Investor Relations Contact:

    Ben Strain, Foghorn Therapeutics Inc.

     

    Hans Vitzthum, LifeSci Advisors

    617-430-7578



    Primary Logo

    View Full Article Hide Full Article
View All Foghorn Therapeutics Inc. News